FGFR2 and acute myeloid leukemia: Although predicted in silico to be benign, FGFR2 K41E, identified in an acute myeloid leukemia, was selected for additional study because of its location in the extracellular Ig1 of FGFR2 and its unknown effect on ligand binding in nearby Ig2 and Ig3 (Data Supplement).